Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Cardinal Health's Sonia T. Oskouei, PharmD, BCMAS, DPLA.
Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.
Transcript
According to Cardinal Health’s 2022 report, only 40% of ophthalmologists reported being “very familiar” with biosimilars. What needs to be included in educational material aimed at these specialists specifically to increase that statistic?
Ophthalmology market research and our own market research at Cardinal Health has really revealed hesitation when it comes to biosimilars at this stage. In fact, when we looked at trends earlier when the first biosimilar was approved and launched in oncology, believe it or not, there were similar perceptions associated biosimilars amongst oncologists. Now, you see the strong adoption that we have an oncology today.
As we're entering these new therapeutic areas, with ophthalmology being the latest, we are seeing this hesitation and lack of familiarity, where there's a desire for more information and the need for more information to help build clinical confidence in these agents. So, any type of data or evidence in understanding of the FDA approval pathway and the associated scientific rigor from the FDA is key to helping build clinical confidence.
I will say in ophthalmology it's almost trickier because unlike oncology and rheumatology, there is not this robust international experience in ophthalmology with ophthalmology biosimilars. In fact, the US is going to be one of the first countries to have an ophthalmology biosimilar available. So, we are positioned to be a source of generating real-world evidence and data to support future confidence in these agents as more products are anticipated to come in the retina space.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.